menu
    • menu
    [{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"QTX3034","moa":"Allosteric KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quanta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"QTX3034","moa":"Allosteric KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quanta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Avidity Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series D Financing","leadProduct":"QTX3034","moa":"Allosteric KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Quanta Therapeutics \/ Avidity Partners","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Avidity Partners"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"QTX3034","moa":"Allosteric KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quanta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"QTX3544","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quanta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"QTX3544","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quanta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"QTX3046","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quanta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quanta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Quanta Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Quanta Therapeutics \/ Surveyor Capital","highestDevelopmentStatusID":"4","companyTruncated":"Quanta Therapeutics \/ Surveyor Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Quanta Therapeutics

    Menu

    Quanta Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QTX3544

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Quanta Announces IND Clearance for QTX3544, Multi-KRAS Inhibitor

                            Details : QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor, being investigated for advanced solid tumors with KRAS G12V mutations.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 08, 2025

                            Lead Product(s) : QTX3544

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QTX3544

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations

                            Details : QTX3544 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 04, 2024

                            Lead Product(s) : QTX3544

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QTX3046,Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Quanta Doses First Patient in Phase 1/1b Trial of QTX3046 and Other Updates

                            Details : QTX3046, a novel orally bioavailable, brain-penetrant, non-covalent allosteric KRASG12D inhibitor has announced dosing of first patient in Phase 1/1b trail for the treatment of advanced solid tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 27, 2024

                            Lead Product(s) : QTX3046,Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QTX3046

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            QTX3046 in Patients With KRAS G12D Mutations

                            Details : QTX3046 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 24, 2024

                            Lead Product(s) : QTX3046

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QTX3034

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            QTX3034 in Patients With KRAS G12D Mutation

                            Details : QTX3034 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 26, 2024

                            Lead Product(s) : QTX3034

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QTX3034

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Quanta Announces IND Clearance By FDA For QTX3034, A Multi-KRAS Inhibitor

                            Details : QTX3034 is a G12D-preferring Multi-KRAS Inhibitor which is being evaluated for the treatment of patients with advanced KRASG12D-mutant solid tumors as monotherapy and in combination with cetuximab.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 04, 2024

                            Lead Product(s) : QTX3034

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QTX3034

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Avidity Partners

                            Deal Size : $50.7 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Quanta Therapeutics Raises Over $50 Million in Series D Financing to Advance its Pipeline of KRAS Inhibitors

                            Details : The proceeds from the financing will be used to advance Quanta’s pipeline including two chemically distinct allosteric KRAS inhibitors, QTX3034, a potent, selective, and orally bioavailable allosteric multi-KRAS inhibitor, and QTX3046, a G12D-selective...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 22, 2023

                            Lead Product(s) : QTX3034

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Avidity Partners

                            Deal Size : $50.7 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QTX3034

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Quanta Therapeutics Announces Two Late-Breaking Preclinical Presentations from KRAS Inhibitor Pipeline at Annu...

                            Details : QTX3034 is a potent, selective and orally bioavailable allosteric KRAS inhibitor which selectively targets protein-protein interactions that are key to oncogenic KRAS activity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 14, 2023

                            Lead Product(s) : QTX3034

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Quanta Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Surveyor Capital

                            Deal Size : $60.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Quanta Therapeutics Announces Oversubscribed $60 Million Series C Financing to Advance Novel RAS-targeting Pro...

                            Details : The Company will use proceeds from this financing round to advance programs targeting RAF1 and KRAS through clinical candidate selection, and IND filing, to reach initial proof-of-concept.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 26, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Surveyor Capital

                            Deal Size : $60.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth